Ezetimibe for lowering blood cholesterol
Canadian Coordinating Office for Health Technology Assessment
Record ID 32003000046
English, French
Authors' objectives:
To summarize the available information on the use of ezetimibe (Ezetrol(TM) in Canada, Zetia(TM) in the United States, manufactured by Merck Frosst-Schering) to reduce the rate of cholesterol absorption by the human small intestine.
Authors' recommendations:
Trials to assess safety and tolerability beyond 12 weeks are ongoing.
Cost-effectiveness analyses speculating on reductions in death and morbidity may be based on short-term randomized controlled trials. These results can overestimate what is achievable in practice.
Producing more lipid target 'responders' with ezetimibe will be appealing, despite the unknown consequences and increased costs. Recent evidence from statin trials suggests that potential benefits could depend on overall coronary artery disease risk and be less reflective of cholesterol levels. The theory that larger cholesterol reductions result in greater reductions in death and hospitalization is being tested with statins.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anticholesteremic Agents
- Azetidines
- Costs and Cost Analysis
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.